Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003906 · ClinicalTrials.gov registry record · Phase 3
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women
A Phase 3 study, sponsored by NSABP Foundation.
- Completed
- Registry status
- Phase 3
- Development phase
- 19,747
- Enrollment target
NCT00003906: Completed Phase 3 study, sponsored by NSABP Foundation.
NCT00003906 is a Phase 3 study that has completed, run by NSABP Foundation. The registered enrollment target is 19,747 participants, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (2461% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003906, a Phase 3 study, has completed, sponsored by NSABP Foundation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 19,747 participants
- Enrollment target
Study Summary
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using raloxifene and tamoxifen may fight breast cancer by blocking the uptake of estrogen by the tumor cells. PURPOSE: Randomized double-blinded clinical trial to compare the effectiveness of raloxifene with that of tamoxifen in preventing breast cancer in postmenopausal women.
Primary Outcome
Determine which of the following is true: 1. compared to tamoxifen, raloxifene significantly reduces the incidence rate of invasive breast cancer; 2. compared to raloxifene, tamoxifen significantly reduces the incidence rate of invasive breast cancer; or 3. the statistical superiority of one of the treatments cannot be demonstrated and the choice of therapy should be based on benefit/risk considerations.
Interventions
- DRUG Tamoxifen
- DRUG Raloxifene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19,747 participants |
| Start Date | 1999-05 |
| Est. Completion | 2012-08 |
| Phase | Phase 3 |
What the finished NCT00003906 record still lists
NCT00003906 is an interventional study that assigns participants to a tested intervention. Its 19,747 participants enrollment target places it among the larger protocols in the corpus, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (2461% higher).
The record links to 0 conditions, and to 2 interventions - of which Tamoxifen is the first listed.
NCT00003906 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00003906 about?
NCT00003906 is a clinical study titled "Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women". RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using raloxifene and tamoxifen may fight breast cancer by blocking the uptake of estrogen by the tumor cells. PURPOSE: Randomized double-blinded clinical trial to compare the effectiveness of raloxifene with that o...
What is the current status of trial NCT00003906?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 19,747 participants. The study started on 1999-05. Estimated completion is 2012-08.
What interventions are being tested in trial NCT00003906?
The interventions under investigation include: Tamoxifen (DRUG), Raloxifene (DRUG).
Who is sponsoring clinical trial NCT00003906?
This trial is sponsored by NSABP Foundation, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00003906's enrollment target sits among peer trials
19,747 11th of 2000 higher than 1,990 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00271180 · 20,000 participants
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
- NCT00830557 · 20,000 participants
Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders
- NCT00900471 · 20,000 participants
Collection and Storage of Tissue Samples From Patients Undergoing Surgery For Suspected Solid Tumors
- NCT02735707 · 20,000 participants · Phase 3
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia